DoximityDOCS
DOCS
About: Doximity Inc is a digital platform for U.S. medical professionals. Its cloud-based platform provides members with tools specifically built for medical professionals, enabling them to collaborate with their colleagues, securely coordinate patient care, conduct virtual patient visits, stay up-to-date with the latest medical news and research, and manage their careers.
Employees: 827
0
Funds holding %
of 6,805 funds
0
Analysts bullish %
of 15 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
100% more funds holding in top 10
Funds holding in top 10: 2 [Q2] → 4 (+2) [Q3]
47% more capital invested
Capital invested by funds: $3.37B [Q2] → $4.95B (+$1.58B) [Q3]
39% more first-time investments, than exits
New positions opened: 71 | Existing positions closed: 51
23% more call options, than puts
Call options by funds: $99M | Put options by funds: $80.6M
6% more funds holding
Funds holding: 326 [Q2] → 346 (+20) [Q3]
7.11% less ownership
Funds ownership: 97.92% [Q2] → 90.81% (-7.11%) [Q3]
28% less repeat investments, than reductions
Existing positions increased: 93 | Existing positions reduced: 129
Research analyst outlook
15 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$33
37%
downside
Avg. target
$53
2%
upside
High target
$75
44%
upside
15 analyst ratings
5 positive
33%
9 neutral
60%
1 negative
7%
Mizuho Steven Valiquette 40% 1-year accuracy 2 / 5 met price target | 5%upside $55 | Neutral Initiated | 4 Dec 2024 |
JP Morgan Anne Samuel 41% 1-year accuracy 7 / 17 met price target | 8%downside $48 | Neutral Maintained | 21 Nov 2024 |
Goldman Sachs David Roman 46% 1-year accuracy 6 / 13 met price target | 11%upside $58 | Neutral Initiated | 15 Nov 2024 |
Truist Securities Jailendra Singh 18% 1-year accuracy 6 / 34 met price target | 6%downside $49 | Hold Maintained | 14 Nov 2024 |
Morgan Stanley Ricky Goldwasser 29% 1-year accuracy 2 / 7 met price target | 2%upside $53 | Equal-Weight Upgraded | 14 Nov 2024 |
Financial journalist opinion
Based on 7 articles about DOCS published over the past 30 days
Positive
Seeking Alpha
1 week ago
Doximity: Strong Fundamentals And Growth Potential Makes It Attractive
Doximity's dominance in digital healthcare is evident with over 80% of U.S. doctors using the platform, driving strong network effects and competitive positioning. The company boasts impressive financials, with earnings surpassing expectations, strong cash reserves, and high margins, indicating robust scalability and efficiency. New AI-powered features and product launches enhance clinical workflows, while leadership's proven track record supports continued market expansion and service broadening.
Positive
Zacks Investment Research
1 week ago
Buy 5 High-Flying Health & Fitness Stocks of 2024 With More Upside
Five Health & Fitness stocks have strong growth potential for 2025. These are GRMN, SFM, DOCS, PLNT and PTON.
Negative
Zacks Investment Research
1 week ago
Are Medical Stocks Lagging Doximity (DOCS) This Year?
Here is how Doximity (DOCS) and AxoGen (AXGN) have performed compared to their sector so far this year.
Positive
Zacks Investment Research
3 weeks ago
3 Momentum Anomaly Stocks to Buy as Election Rally Fizzles
DOCS, PI and INOD are currently witnessing a short-term pullback in price. So, make sure you take full advantage of it.
Positive
Zacks Investment Research
3 weeks ago
Looking for Earnings Beat? Buy These 4 Top-Ranked Stocks
Top-ranked stocks Amazon.com (AMZN), Maplebear Inc. (CART), Exelixis (EXEL) and Doximity (DOCS) are likely to beat on the bottom line in their upcoming releases.
Positive
Zacks Investment Research
4 weeks ago
Surging Earnings Estimates Signal Upside for Doximity (DOCS) Stock
Doximity (DOCS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Positive
Seeking Alpha
4 weeks ago
Doximity Q2 Earnings: Positioning Is Paying Off
I rate Doximity a buy with a price target of $65, reflecting a 24% upside due to strong Q2 earnings and favorable industry trends. Doximity's Q2 earnings showed impressive revenue growth, margin expansion, and a revised forecast of 36% CAGR in revenue and 74% CAGR in Adjusted EBITDA. Positioned at the intersection of healthcare trends, Doximity offers cost-saving solutions that align with industry needs, supporting double-digit growth through 2030.
Positive
The Motley Fool
1 month ago
Why Doximity Stock Is Skyrocketing Today
The market loved what it saw from Doximity's second-quarter earnings.
Positive
Investopedia
1 month ago
Why Doximity Stock is Set to Open at Highest Point in Over 2 Years Friday
Doximity (DOCS) shares jumped nearly 40% in premarket trading Friday after the medical tech company's earnings and outlook came in above what analysts expected.
Positive
Barrons
1 month ago
Doximity Stock Soars 42% Toward Best Day Ever. It's Not the Only Record.
The online medical platform reported quarterly revenue of $136.8 million and earnings of 30 cents a share, beating analysts expectations.
Charts implemented using Lightweight Charts™